{"organizations": [], "uuid": "c09725da27a41de5b839f095e4169273dbb23345", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://www.reuters.com/resources/archive/us/20180515.html", "section_title": "Archive News &amp; Video for Tuesday, 15 May 2018 | Reuters.com", "url": "https://www.reuters.com/article/brief-fda-approves-expanded-indication-f/brief-fda-approves-expanded-indication-for-truvada-idUSASO0004U7", "country": "US", "domain_rank": 408, "title": "BRIEF-FDA Approves Expanded Indication For Truvada", "performance_score": 0, "site": "reuters.com", "participants_count": 1, "title_full": "", "spam_score": 0.902, "site_type": "news", "published": "2018-05-16T00:55:00.000+03:00", "replies_count": 0, "uuid": "c09725da27a41de5b839f095e4169273dbb23345"}, "author": "Reuters Editorial", "url": "https://www.reuters.com/article/brief-fda-approves-expanded-indication-f/brief-fda-approves-expanded-indication-for-truvada-idUSASO0004U7", "ord_in_thread": 0, "title": "BRIEF-FDA Approves Expanded Indication For Truvada", "locations": [], "entities": {"persons": [], "locations": [{"name": "u.s.", "sentiment": "none"}, {"name": "truvada", "sentiment": "none"}, {"name": "truvada", "sentiment": "none"}], "organizations": [{"name": "reuters", "sentiment": "negative"}, {"name": "gilead sciences inc", "sentiment": "negative"}, {"name": "thomson reuters trust principles", "sentiment": "none"}, {"name": "eikon", "sentiment": "none"}, {"name": "gilead", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "May 15 (Reuters) - Gilead Sciences Inc:\n* U.S. FOOD AND DRUG ADMINISTRATION APPROVES EXPANDED INDICATION FOR TRUVADAÂ® (EMTRICITABINE AND TENOFOVIR DISOPROXIL FUMARATE) FOR REDUCING THE RISK OF ACQUIRING HIV-1 IN ADOLESCENTS\n* GILEAD SCIENCES - U.S. FDA HAS APPROVED ONCE-DAILY ORAL TRUVADA TO REDUCE RISK OF SEXUALLY ACQUIRED HIV-1 IN AT-RISK ADOLESCENTS Source text for Eikon: Further company coverage:\nOur Standards: The Thomson Reuters Trust Principles. ", "external_links": ["https://twitter.com/reuters", "https://www.youtube.com/user/ReutersVideo", "https://www.linkedin.com/company/10256858/", "https://www.facebook.com/Reuters", "https://www.thomsonreuters.com/en/privacy-statement.html", "http://thomsonreuters.com/en/about-us/trust-principles.html", "https://instagram.com/reuters/"], "published": "2018-05-16T00:55:00.000+03:00", "crawled": "2018-05-16T18:51:38.056+03:00", "highlightTitle": ""}